Jeffrey H. Meyer
MD, PhD, FRCP(C)
Dr. Meyer’s priorities are identifying mechanisms of treatment-resistant depression and prevention of major depressive episodes, through identifying and understanding modifiable biological markers related to onset, and persistence of major depressive episodes. His current targets of interest are neuroinflammatory markers of gliosis, mitochondrial markers (like monoamine oxidase A and monoamine oxidase B), and markers of synaptic density. He primarily applies neuroimaging, but also uses related markers in preclinical approaches, towards understanding mechanisms. He is also involved in early phase trials of novel therapeutics, phase 0 trials to target pathological markers of depression, the development of new natural health products and the creation of novel peripheral biomarkers of mood disorders.
Techniques include: positron emission tomography, biomarker development, MR spectroscopy, human clinical trials, cognitive testing, Western blot, enzyme assays, natural health product development.
Current research directions include:
- PET investigation of neurochemical abnormalities in Major Depressive Episodes Comorbid Psychiatric Illnesses, and High Risk States for Major Depressive Episodes (including neuroinflammation and monoamine oxidase)
- Recurrence of Major Depressive Episodes
- Postpartum Depression
- Traumatic Brain Injury
- Antidepressant Occupancy
- Antidepressant Effects on Pathophysiology and Dimensions of Illness
- Prevention Strategies Against Onset of Major Depressive Episodes